Home LiteratureArticle Details
PMID: 15635002 Published · ppublish English Comparative Study Evaluation Study Journal Article Research Support, U.S. Gov't, P.H.S.

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Journal of clinical microbiology ·Vol. 43 ·No. 1 ·2005-01-00 ·Pages 406-13

Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM

Abstract

To investigate the extent to which drug resistance mutations are missed by standard genotyping methods, we analyzed the same plasma samples from 26 patients with suspected multidrug-resistant human immunodeficiency virus type 1 by using a newly developed single-genome sequencing technique and compared it to standard genotype analysis. Plasma samples were obtained from patients with prior exposure to at least two antiretroviral drug classes and who were on a failing antiretroviral regimen. Standard genotypes were obtained by reverse transcriptase (RT)-PCR and sequencing of the bulk PCR product. For single-genome sequencing, cDNA derived from plasma RNA was serially diluted to 1 copy per reaction, and a region encompassing p6, protease, and a portion of RT was amplified and sequenced. Sequences from 15 to 46 single viral genomes were obtained from each plasma sample. Drug resistance mutations identified by single-genome sequencing were not detected by standard genotype analysis in 24 of the 26 patients studied. Mutations present in less than 10% of single genomes were almost never detected in standard genotypes (1 of 86). Similarly, mutations present in 10 to 35% of single genomes were detected only 25% of the time in standard genotypes. For example, in one patient, 10 mutations identified by single-genome sequencing and conferring resistance to protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors, and nonnucleoside reverse transcriptase inhibitors (NNRTIs) were not detected by standard genotyping methods. Each of these mutations was present in 5 to 20% of the 20 genomes analyzed; 15% of the genomes in this sample contained linked PI mutations, none of which were present in the standard genotype. In another patient sample, 33% of genomes contained five linked NNRTI resistance mutations, none of which were detected by standard genotype analysis. These findings illustrate the inadequacy of the standard genotype for detecting low-frequency drug resistance mutations. In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis.

MeSH Terms
Anti-HIV Agents/pharmacology Drug Resistance, Multiple, Viral/genetics Genome, Viral Genotype HIV Infections/drug therapy,virology HIV Protease/genetics HIV Reverse Transcriptase/genetics HIV-1/drug effects,genetics Humans Microbial Sensitivity Tests/methods,standards Mutation RNA, Viral/genetics,isolation & purification Reverse Transcriptase Inhibitors/pharmacology Sensitivity and Specificity Sequence Analysis, DNA
Chemicals
Anti-HIV Agents RNA, Viral Reverse Transcriptase Inhibitors HIV Reverse Transcriptase HIV Protease
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Palmer Sarah
HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. spalmer@ncifcrf.gov
Kearney Mary
Maldarelli Frank
Halvas Elias K
Bixby Christian J
Bazmi Holly
Rock Diane
Falloon Judith
Davey Richard T
Dewar Robin L
Metcalf Julia A
Hammer Scott
Mellors John W
Coffin John M
References (47)
47 references, click to expand
  1. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
    J Infect Dis. 2003 Nov 15;188(10):1433-43 PMID: 14624368
  2. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.
    AIDS Res Hum Retroviruses. 1998 Jul 1;14(10):869-76 PMID: 9671215
  3. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.
    J Virol. 2004 Apr;78(8):4234-47 PMID: 15047838
  4. Fidelity of HIV-1 reverse transcriptase.
    Science. 1988 Nov 25;242(4882):1168-71 PMID: 2460924
  5. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.
    J Virol Methods. 1998 Nov;75(1):93-104 PMID: 9820578
  6. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.
    Lancet. 1999 Jun 26;353(9171):2195-9 PMID: 10392984
  7. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
    J Infect Dis. 2010 Mar;201(5):672-80 PMID: 20102272
  8. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
    J Virol. 1999 Dec;73(12):10489-502 PMID: 10559367
  9. A strategy for cloning infectious molecular clones of retroviruses from serum or plasma.
    J Virol Methods. 2000 Jan;84(1):37-48 PMID: 10644085
  10. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
    Antivir Ther. 2000 Mar;5(1):41-8 PMID: 10846592
  11. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    AIDS. 2000 Jun 16;14(9):F83-93 PMID: 10894268
  12. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84 PMID: 10952598
  13. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    N Engl J Med. 2001 Feb 15;344(7):472-80 PMID: 11172188
  14. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.
    AIDS. 2001 Feb 16;15(3):309-20 PMID: 11273210
  15. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
    J Virol. 2001 Jul;75(14):6410-7 PMID: 11413308
  16. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.
    AIDS. 2001 Nov 9;15(16):2189-91 PMID: 11684940
  17. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy.
    J Clin Virol. 2002 Feb;24(1-2):93-8 PMID: 11744433
  18. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.
    AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):243-8 PMID: 11860670
  19. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    JAMA. 2002 Jul 10;288(2):169-80 PMID: 12095381
  20. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases.
    Prog Nucleic Acid Res Mol Biol. 2002;71:91-147 PMID: 12102562
  21. Virus population homogenization following acute human immunodeficiency virus type 1 infection.
    J Virol. 2002 Dec;76(23):11953-9 PMID: 12414937
  22. Retroviral mutation rates and reverse transcriptase fidelity.
    Front Biosci. 2003 Jan 1;8:d117-34 PMID: 12456349
  23. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity.
    J Virol Methods. 2003 May;109(2):161-70 PMID: 12711059
  24. Multiple sequence alignment with the Clustal series of programs.
    Nucleic Acids Res. 2003 Jul 1;31(13):3497-500 PMID: 12824352
  25. HIV sequence databases.
    AIDS Rev. 2003 Jan-Mar;5(1):52-61 PMID: 12875108
  26. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
    N Engl J Med. 2003 Aug 28;349(9):837-46 PMID: 12944569
  27. HIV resistance testing. A clinical tool.
    N J Med. 2003 Sep;100(9 Suppl):44-9; quiz 75-6 PMID: 14556603
  28. The accuracy of reverse transcriptase from HIV-1.
    Science. 1988 Nov 25;242(4882):1171-3 PMID: 2460925
  29. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1990 Dec;64(12):5840-50 PMID: 2243378
  30. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates.
    AIDS. 1991 Jun;5(6):675-81 PMID: 1715717
  31. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.
    Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4835-9 PMID: 1594583
  32. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    J Virol. 1994 Mar;68(3):1660-6 PMID: 7509000
  33. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.
    J Virol. 1995 Jan;69(1):23-31 PMID: 7983713
  34. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
    Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 PMID: 7984417
  35. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
    Science. 1995 Jan 27;267(5197):483-9 PMID: 7824947
  36. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
    Nature. 1995 Apr 6;374(6522):569-71 PMID: 7700387
  37. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.
    J Virol. 1995 Aug;69(8):5087-94 PMID: 7541846
  38. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.
    PCR Methods Appl. 1995 Jun;4(6):357-62 PMID: 7580930
  39. HIV quasispecies and resampling.
    Science. 1996 Jul 26;273(5274):415-6 PMID: 8677432
  40. Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy.
    AIDS. 1996 Sep;10(10):1067-73 PMID: 8874622
  41. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
    J Virol. 1996 Nov;70(11):7894-9 PMID: 8892912
  42. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
    J Virol. 1996 Dec;70(12):8270-6 PMID: 8970946
  43. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
    JAMA. 1997 Jun 25;277(24):1962-9 PMID: 9200638
  44. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles.
    Virology. 1998 Feb 15;241(2):251-9 PMID: 9499799
  45. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.
    J Virol. 1998 Jun;72(6):5303-6 PMID: 9573309
  46. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.
    Ann Intern Med. 1998 Jun 1;128(11):906-11 PMID: 9634429
  47. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
    J Infect Dis. 2004 Mar 15;189(6):1091-6 PMID: 14999613
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
Published
2005-01-00
Pages
406-13
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC540111
Subset
IM
Grants
NIAID NIH HHS · U01 AI038858 · United States
NIAID NIH HHS · U01AI38858 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com